Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis-Reference-Cited by-同舟云学术

Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis

Published:2023-06-29 Issue:9 Volume:19 Page:1131-1142
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Farina N¹^ORCID,Campochiaro C¹²^ORCID,Lescoat A³,Benanti G¹²^ORCID,De Luca G¹²,Khanna D⁴,Dagna L¹²,Matucci-Cerinic M¹⁵

Affiliation:

1. Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Italy

2. Vita-Salute San Raffaele University, Milan, Italy

3. Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France

4. Department of Internal Medicine, University of Michigan, Ann Arbor, USA

5. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2023.2230370

Reference136 articles.

1. The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis

2. Systemic sclerosis

3. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

4. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

5. Khanna D, Bush E, Nagaraja V, et al. Tofacitinib in early diffuse cutaneous systemic sclerosis— results of phase i/ii investigator-initiated, double-blind randomized placebo-controlled trial - ACR meeting abstracts.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies;Antibodies;2024-02-01